Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 19 JANUARY 2026

The Buzz: 2025 Year In Review

Holland & Hart LLP
Explore more from Holland & Hart LLP

As we reflect on the whirlwind that was 2025, we find ourselves cautiously optimistic about the path ahead for the cannabis industry.

United StatesCannabis & Hemp
Rachel Gillette
Rachel Gillette
Jennifer Benda
Jennifer Benda

As we reflect on the whirlwind that was 2025, we find ourselves cautiously optimistic about the path ahead for the cannabis industry. While the year brought both unprecedented federal action and intensifying challenges, we believe the momentum toward sensible cannabis policy reform continues to build. We hope you'll continue to read and subscribe to “the buzz” as we navigate these transformative times together.

CANNABIS INDUSTRY YEAR IN REVIEW: 2025

The cannabis industry experienced a year of unprecedented federal action alongside intensifying state-level polarization in 2025, setting the stage for what promises to be a transformative 2026.

FEDERAL BREAKTHROUGH AFTER YEARS OF GRIDLOCK?

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Article

The Intoxicating Hemp Products Ban Was Delayed A Month. Now What?

The House has passed a short-term funding bill postponing the federal ban on hemp-derived THC products from November 12th to December 11th. With comprehensive legislation unlikely before the new deadline and competing interests from cannabis sellers, alcohol producers, and state regulators creating policy gridlock, the future of intoxicating hemp products remains uncertain as midterm elections approach.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

IRC Section 280E And Cannabis Tax Planning: Recent Developments And Practical Considerations

The landscape surrounding Section 280E of the Internal Revenue Code continues to evolve with President Trump's Executive Order on medical marijuana rescheduling, advancing litigation in New Mexico Top Organics v. Commissioner, and shifting regulatory signals. Cannabis taxpayers face critical decisions about taking "non-280E" positions on their tax returns while the IRS maintains its enforcement stance and the U.S. Tax Court case addressing common arguments remains pending.
United StatesCannabis & Hemp
Foley Hoag LLP
Foley Hoag LLP
Article

"Marijuana" Rescheduling Delayed, Again. What It Could Mean, And What Comes Next

The DEA's marijuana rescheduling hearing has been unexpectedly stayed following a motion to admit a new GAO report examining agency scheduling procedures. With the proceeding on hold and the medical marijuana Schedule III order facing legal challenges in the D.C. Circuit, the cannabis industry's path to federal tax relief through rescheduling has become increasingly uncertain.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski